U.S. Markets close in 2 hrs 2 mins

See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

IHS Markit

Alder Biopharmaceuticals Inc

NASDAQ NMS:ALDR

Score: Negative (18)

1 day at current score.

Downgraded from Neutral on February 23rd 2018

View full report here!

Summary


  • This company ranked negatively compared to the Healthcare sector with 2 negative IHS Markit Categories
  • ETFs holding this stock have seen outflows over the last one-month
  • Bearish sentiment is moderate and increasing


Bearish sentiment

Short interest | Negative

Short interest is moderately high for ALDR with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on February 12.

Money flow

ETF/Index ownership | Negative

ETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ALDR totaled $656 million. Additionally, the rate of outflows appears to be accelerating.

Economic sentiment

PMI by IHS Markit | Neutral

According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however.

Credit worthiness

Credit default swap

CDS data is not available for this security.

Please send all inquiries related to the report to score@ihsmarkit.com.

Charts and report PDFs will only be available for 30 days after publishing.

This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.